Haimeng Tang (Jerry)

Jerry graduated with a BSc in Biotechnology from University of Toronto and obtained an MSc from Brock University in 2021. He works at Geneseeq as a bioinformatician, where he tackles all sorts of oncology-related problems.

In the webinar, three studies utilizing IDT’s custom xGen™ hybridization capture panels with circulating tumor DNA (ctDNA) for the analysis of minimal residual disease (MRD) are presented. Learn how this approach has been used to assist with assessing neoadjuvant or adjuvant therapies, stratifying relapse risk, as well as relapse prior to radiographic imaging in lung and colorectal cancer cases. Bringing these studies into the spotlight, this will encourage researchers to further explore the benefits of MRD analysis within their translational research studies.